Halozyme Therapeutics (HALO) Change in Receivables (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Change in Receivables data on file, last reported at $19.5 million in Q1 2026.

• Change in Receivables for Q1 2026 came in at $19.5 million, up 609.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $151.4 million (up 39.3% YoY), and the FY2025 annual result was $128.1 million, up 72.49% from the prior year.
• Change in Receivables declined to $19.5 million in Q1 2026 per HALO's latest filing, from $90.5 million in the prior quarter.
• Over five years, Change in Receivables peaked at $90.5 million in Q4 2025 and troughed at -$38.3 million in Q1 2024.
• A 5-year average of $18.2 million and a median of $18.6 million in 2024 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2023 and 2026: Change in Receivables plunged 258.81% in 2023, then surged 609.83% in 2026.
• A 5-year view of Change in Receivables shows it stood at $7.8 million in 2022, then surged by 117.73% to $16.9 million in 2023, then surged by 34.51% to $22.7 million in 2024, then jumped by 298.39% to $90.5 million in 2025, then sank by 78.4% to $19.5 million in 2026.
• Business Quant data shows HALO's Change in Receivables at $19.5 million in Q1 2026, $90.5 million in Q4 2025, and $29.7 million in Q3 2025.